Insider Selling: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Insider Sells 16,848 Shares of Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insider George Yancopoulos sold 16,848 shares of the business’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $900.00, for a total transaction of $15,163,200.00. Following the completion of the sale, the insider now directly owns 180,000 shares in the company, valued at approximately $162,000,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Regeneron Pharmaceuticals Trading Up 1.4 %

REGN opened at $903.48 on Thursday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The firm has a market capitalization of $99.17 billion, a PE ratio of 26.00, a P/E/G ratio of 2.55 and a beta of 0.17. The company’s 50-day moving average is $944.78 and its 200 day moving average is $895.25.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. During the same quarter in the prior year, the business posted $10.96 EPS. The firm’s revenue was up .6% compared to the same quarter last year. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.86 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on REGN. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. UBS Group boosted their price objective on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. Barclays boosted their price objective on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 23rd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Finally, Bank of America upped their price target on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research report on Friday, April 12th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $977.77.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Norges Bank purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at about $932,571,000. FMR LLC increased its stake in Regeneron Pharmaceuticals by 7.3% in the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock valued at $8,098,661,000 after buying an additional 669,517 shares during the last quarter. International Assets Investment Management LLC increased its stake in Regeneron Pharmaceuticals by 76,169.5% in the 4th quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock valued at $519,148,000 after buying an additional 590,314 shares during the last quarter. Global Assets Advisory LLC purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at about $339,594,000. Finally, First Trust Advisors LP increased its stake in Regeneron Pharmaceuticals by 115.2% in the 4th quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock valued at $321,410,000 after buying an additional 195,902 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.